Biologics Seem to be the Best for Psoriasis Patients


eMediNexus    19 January 2018

A Cochrane meta-analysis noted that all major treatment classes reviewed were more effective than placebo for moderate to severe psoriasis; however, biologic agents appeared to be the most efficacious. Evaluation of data from 109 studies revealed that anti-IL17, anti-IL12/23, anti-IL23, and anti-TNF alpha drugs were superior for achieving PASI 90 status (90% reduction in Psoriasis Area and Severity Index score). All of the anti-IL17 drugs and guselkumab were found to be more effective than the anti-TNF alpha drugs infliximab, adalimumab, and etanercept for attaining PASI 90 status. Ustekinumab, an IL-12/23 inhibitor, was better than etanercept. Tofacitinib was superior to methotrexate. The findings are published online in Cochrane Library.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.